India’s bulk drug PLI programme had attracted ₹5,210.74 crore of investment by June 2026, exceeding the ₹4,330 crore committed across approved projects. Thirty-nine projects covering 28 pharmaceutical inputs are commissioned. The result is real capacity, but the bulk drug PLI still has to prove that those plants reduce vulnerable imports at competitive cost.
bulk drug PLI: verified facts
| Disclosure date | 25 September 2026 |
|---|---|
| Investment as of June 2026 | ₹5,210.74 crore |
| Approved projects | 48 |
| Commissioned projects | 39 |
| Products commissioned | 28 APIs, KSMs and drug intermediates |
| Reported sales | ₹3,792.49 crore |
| Reported exports | ₹560.16 crore |
| Reported employment | About 5,127 jobs |
What the bulk drug PLI update verifies
The Department of Pharmaceuticals says 48 projects were approved under the ₹6,940 crore scheme. As of June, 39 projects had been commissioned, generating ₹3,792.49 crore in sales, including ₹560.16 crore in exports, and about 5,127 jobs. The release names strategic inputs including Penicillin-G, Clavulanic Acid and Rifampicin. These are cumulative programme figures, not a new investment round or a forecast.
Commissioning is the midpoint
A commissioned plant shows that capital has become physical capacity. It does not show reliable utilisation, acceptable yields or enduring customer qualification. Pharmaceutical buyers validate quality and supply consistency over time. The next disclosures should therefore separate installed capacity from actual production and show how many approved products are selling at commercial scale.
Import substitution needs product-level proof
Financial Express notes that China remains a major source of pharmaceutical input imports despite PLI progress. That does not negate the new plants; it defines the benchmark. A credible scorecard should compare import volumes, domestic output, landed cost and supplier concentration for each supported molecule. Aggregate sales can rise while exposure in a few critical APIs remains unchanged.
Economics matter after incentives
The scheme was designed to offset disadvantages in infrastructure, utilities and scale. Once plants run, the relevant test is whether they can compete after incentive support declines. Energy use, fermentation yield, solvent recovery, environmental compliance and working-capital cycles can determine whether domestic supply is durable. Export sales are useful evidence, but they should not be double-counted as proof of domestic substitution.
What companies should disclose next
Programme reporting should add plant-level commissioning dates, capacity utilisation, domestic versus export sales and the share of output covered by long-term contracts. It should also distinguish APIs from intermediates, because the strategic value differs. Everyone else is reporting the investment total; the better question is whether the plants create a resilient, cost-competitive supply chain for specific medicines.
The practical takeaway
The September disclosure is an implementation update, not a declaration of self-reliance. It shows that commitments have moved into factories and sales. The next stage is harder: repeatable quality, economic production and measurable reduction in concentrated imports. That is where industrial policy becomes an operating result rather than a sanctioned project list.
Related Lapaas Voice coverage
PLI manufacturing scale faces a depth test, Jagsonpal acquisition ties price to operations, Hyderabad–Brussels route targets pharma flows.
Frequently asked questions
How much investment has the bulk drug PLI attracted?
The government reported ₹5,210.74 crore as of June 2026.
How many projects are operating?
Thirty-nine approved projects covering 28 products were reported commissioned.
Does this mean India is self-reliant in APIs?
No. Commissioning and sales are progress indicators, but product-level import dependence and cost competitiveness still need to be measured.
What is the scheme outlay?
The bulk drug PLI was approved with a ₹6,940 crore outlay.
Disclosure date: 25 September 2026. This analysis is not investment advice.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
